Advertisement
Table 6 Impact of expression of PD-L1 on disease-free and overall survival tested by log-rank analysis
| Parameters | Number of patients /recurrence/death | Disease-free survival | Overall survival | ||
|---|---|---|---|---|---|
| Mean survival (95 % CI) months | p value | Mean survival (95 % CI) months | p value | ||
| PD-L1 (28-8) (T) | N/A | 0.967 | |||
| Negative | 191/16/17 | N/A | 91 (87–95) | ||
| Positive | 27/0/2 | N/A | 59 (54–64) | ||
| PD-L1 (E1L3N) (T) | N/A | 0.647 | |||
| Negative | 186/16/17 | N/A | 90 (86–95) | ||
| Positive | 32/0/2 | N/A | 91 (84–98) | ||
| PD-L1 (28-8) (I) | 0.043 | 0.021 | |||
| Negative | 138/14/17 | 89 (84–93) | 87 (82–92) | ||
| Positive | 80/2/2 | 97 (94–100) | 97 (94–100) | ||
| PD-L1 (E1L3N) (I) | 0.761 | 0.255 | |||
| Negative | 136/11/15 | 91 (87–95) | 88 (84–93) | ||
| Positive | 82/5/4 | 94 (89–98) | 95 (90–99) | ||
| PD-L1 (SP142) (I) | 0.191 | 0.387 | |||
| Negative | 176/15/17 | 90 (86–94) | 89 (85–93) | ||
| Positive | 42/1/2 | 97 (93–101) | 95 (89–100) | ||
